Background For its low cost and ease of handling, the mouse remains the preferred experimental
animal for preclinical tests. To avoid the interaction of the animal immune system, in …

Recent studies have reported that Staphylococcus aureus small colony variants (SCVs) can
cause highly persistent infections in humans and in cultured endothelial cells. To …

While S. aureus small colony variants (SCVs) have been recognized in clinical materials for
decades, only recently have these strains been linked to persistent, resistant, and relapsing …

Background Although bone specimens were established 25 years ago as the gold standard
for etiologic diagnosis of chronic osteomyelitis, recent studies suggest that nonbone …

Generic versions of intravenous antibiotics are not required to demonstrate therapeutic
equivalence with the innovator because therapeutic equivalence is assumed from …

Background Prognosis of chronic osteomyelitis depends heavily on proper identification
and treatment of the bone-infecting organism. Current knowledge on selecting the best …

Background Demonstration of equivalent amounts of the same active pharmaceutical ingredient
(API) between generic and innovator products (pharmaceutical equivalence) is a basic …

Background Drug regulatory agencies (DRA) support prescription of generic products of
intravenous antibiotics assuming therapeutic equivalence from pharmaceutical equivalence. …

Background Oxacillin continues to be an important agent in the treatment of staphylococcal
infections; many generic products are available and the only requirement for their approval is …

Previous studies have shown that “bioequivalent” generic products of vancomycin are less
effective in vivo against Staphylococcus aureus than the innovator compound. Considering …